The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progress...
The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice
About this item
Full title
Author / Creator
Publisher
England: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Tofogliflozin may prevent glomerular (enlarged mesangial area, foot process effacement, podocyte loss) and tubulointerstitial damage (increased expression of MCP‐1 and KIM‐1), partly by ameliorating hyperglycemia, renal inflammation, and abnormal mitochondrial morphology.
Trials on cardiovascular and renal outcomes in patients with type 2 diabet...
Alternative Titles
Full title
The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7714078
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7714078
Other Identifiers
ISSN
2211-5463
E-ISSN
2211-5463
DOI
10.1002/2211-5463.13014
